Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX007 in Primary Open-angle Glaucoma
NCT03488550Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vonaprument in primary open-angle glaucoma (POAG), sponsored by Annexon Biosciences. Primary endpoint: Occurrence of adverse events at Day 56. Started Mar 2018; status: completed.
02
Drugs
vonaprument
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT03488550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488550.